Full-Time
Assistant Corporate Controller
Updated on 9/9/2026
Azenta
1,001-5,000 employees
Automated cold-chain sample management and multiomics
Compensation Overview
$162k - $202k/yr
Burlington, MA, USA
Hybrid
Four days on-site per week are expected in the Burlington executive offices; travel to other company sites and events may be required.
 Accounting (1) |
|---|
Get referred to Azenta
See people who can refer or advise you
- 10+ years in an accounting or finance leadership role within a publicly traded company or public accounting firm.
- A Certified Public Accountant credential is required.
- Public accounting experience is required.
- Experience leading a corporate accounting function for a United States-based publicly traded company with international operations, or auditing a global publicly traded company.
- A demonstrated track record of driving process improvements.
- Demonstrated success in dynamic, growth environments with varying business requirements.
- Exceptional written and verbal communication skills, including the ability to articulate recommendations concisely.
- Strategic thinking and leadership capabilities, with the ability to assess, organize, plan, and execute projects from conceptualization through implementation across multiple internal and external reporting and organizational lines.
- Extensive knowledge of United States generally accepted accounting principles and a strong understanding of financial and information technology controls and Sarbanes-Oxley requirements.
- Experience with a large-scale enterprise resource planning system and financial consolidation systems is required.
- Lead and develop a high-performing team of accounting professionals while promoting a culture of continuous improvement.
- Manage the global monthly closing cycle, including oversight of consolidations, corporate accounting, shared services, and support for the financial reporting function.
- Manage accounting and financial operations for a complex, multi-entity, multi-currency global company while ensuring compliance with United States generally accepted accounting principles, local accounting requirements, internal policies, and Securities and Exchange Commission reporting requirements.
- Provide financial oversight, guidance, and thought partnership to divisional accounting teams.
- Build meaningful and trusted relationships with key internal stakeholders across business units and functions.
- Continuously review and enhance financial policies, procedures, internal controls, and systems to align with best practices and evolving business needs.
- Serve as a liaison with external auditors on significant judgments and accounting matters.
- Partner with finance, tax, treasury, legal, information technology, and business teams on cross-functional initiatives affecting accounting and reporting.
- Support newly acquired businesses with training and guidance on corporate accounting policies to ensure financial results are prepared in accordance with generally accepted accounting principles and internal accounting policies.
- Support preparation or review of materials for presentation to executive management or the Audit Committee of the Board of Directors.
- Execute and ensure compliance with key internal controls and consistently review current controls to determine the adequacy and sufficiency of their design.
- Big Four public accounting experience is preferred.
- Experience with Oracle, NetSuite, or OneStream is a plus.
Azenta provides end-to-end life sciences solutions focused on sample management and genomic services. Its SMS segment offers automated ultra-cold storage, cryogenics, consumables, instruments, and repository services, while the Multiomics segment (GENEWIZ) provides genomic services like sequencing and gene synthesis. The company integrates hardware, consumables, software, and biorepository capabilities to collect, store, and analyze samples across pharma, biotech, academia, and healthcare, with about 55% recurring revenue. Its goal is to speed up drug development, clinical research, and advanced cell therapies by maintaining sample integrity from collection to data analysis.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Burlington, Massachusetts
Founded
1978
Get referred to Azenta
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q3 fiscal 2026 revenue reached $161 million, up 12%, with 9% organic growth.
- Azenta raised FY2026 revenue guidance to $613-$618 million after stronger biorepositories.
- Thelema repaid the $35 million B Medical vendor loan on September 3, 2026.
What critics are saying
- John Marotta resigned August 22, 2026, forcing Martin Madaus into a temporary CEO seat.
- Q2 2026 recorded a $149 million goodwill impairment across Multiomics and SMS.
- By FY2027, persistent impairments and stalled growth force another breakup, destroying Azenta's standalone model.
What makes Azenta unique
- Azenta's 2026 portfolio spans sample repositories, automated cold storage, and multiomics services.
- UK Biocentre added a European-wide biorepository hub on March 4, 2026.
- Its custom PCR manufacturing in ISO 9001 and 13485 facilities beats catalog commoditization.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Flexible Work Hours
Company News
Why Cleveland Clinic's research chief welcomed a budget for its biggest research investment. By: Kelly Gooch For Serpil Erzurum, MD, the decision to build two research buildings on Cleveland Clinic's main campus was an investment in the future of the health system's research and innovation strategy. It also marked the largest research investment in the organization's more than 100-year history. The two buildings, which opened in early September, total 300,000 square feet and are designed to house more than 700 employees across nearly 30 laboratories and core service areas. Cleveland Clinic said the project is part of a broader effort to expand biomedical research within the Cleveland Innovation District. For Dr. Erzurum, executive vice president and chief research and academic officer at Cleveland Clinic, the project required the same kind of trade-offs health system executives face in other parts of the organization. "A defined budget requires us to establish priorities, make deliberate trade-offs, and direct resources toward the choices that will have the greatest impact. Working within defined constraints ensures that we focus on what matters most, rather than trying to do everything. We make more intentional decisions, have greater focus, and ultimately accelerate outcomes," she said. Dr. Erzurum said the investment builds on Cleveland Clinic's longstanding mission around patient care, research and education while reflecting how scientific work has changed. Advances in genomics, protein metabolism, large-scale data and computational sciences have expanded both the questions researchers can ask and the technologies by which they answer them. The buildings were designed around that shift. Laboratories are grouped into what Dr. Erzurum described as "neighborhoods" of science and innovation, with open layouts intended to encourage communication and collaboration. The facilities connect with high-performance and quantum computing capabilities, and include agentic AI laboratories where computational scientists are working on discovery and innovation. "Laboratories today are fundamentally different from those of even five or ten years ago - more technology-enabled, collaborative, flexible, and purpose-built to support increasingly complex research and innovation." Dr. Erzurum said. Asked why Cleveland Clinic chose to make the investment now, she pointed to the speed of scientific discovery and to health challenges that have evolved significantly over the past two decades. "The opportunity to invest in science has never been greater or more consequential. This is precisely the moment to invest," she said, pointing to transformative challenges and opportunities in areas such as pathogen research and inflammation, cancer and neurodegenerative diseases." The project is part of the Cleveland Innovation District, a public-private initiative supported by the state of Ohio and JobsOhio. Cleveland Clinic has also developed partnerships with organizations including IBM, Canon Medical and Azenta, while Miami University in Oxford, Ohio, has established a presence in the district and sent interns to work on quantum and computational science projects. Dr. Erzurum said the system is looking beyond traditional research output when evaluating the broader return from the investment. Cleveland Clinic has created nearly 2,000 jobs tied to the innovation district over the past five years, and she said the people working in the new laboratories will also contribute to surrounding economic and workforce growth. "An innovation district is more than a place where people work. It is an ecosystem where people live, work, connect, and engage. When these districts are thoughtfully developed, they can catalyze investment, attract talent, strengthen surrounding neighborhoods, and bring new energy to a city. The impact extends well beyond science and technology, creating opportunities for the arts, culture, retail, and broader community to grow and prosper alongside that investment." For executives at other health systems, Dr. Erzurum said the transferable lesson is how organizations decide what deserves scarce resources. "There will never be unlimited resources. Effective leadership requires making deliberate choices about where to invest," she said. "At Cleveland Clinic, we have made a strategic decision to prioritize innovation as a driver of healthcare transformation." She said that Cleveland Clinic views research as an investment expected to create future value rather than as discretionary spending. "It is about investing in the future and creating sustainable value," Dr. Erzurum said. "When we invest strategically in opportunities, we create value that extends well beyond the initial investment." Dr. Erzurum said the budget influenced how the space was built and what equipment the team purchased. She compared their approach to a household budget: setting priorities and allocating resources where they matter most rather than trying to fund everything at once. "When you establish clear priorities, you move faster, align the team, and create clarity around what matters most," she said. "Science works the same way. Focus creates momentum, and discipline is what turns discovery into results and innovation." At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14-17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now. Thursday, September 17 1:00 PM - 2:00 PM CDT Presenter: Melinda Giese, Enterprise Client Solutions, CHG Healthcare Next up in financial management. * 'We're here for the long term': Henry Ford doubles down on Medicare Advantage as others retreat As insurers and provider-sponsored health plans reassess their exposure to Medicare Advantage, Detroit-based Henry Ford Health is moving in the... By: Alan Condon * RWJBarnabas posts 6.4% operating margin in H1 West Orange, N.J.-based RWJBarnabas Health recorded an operating income of $385.8 million (6.4% operating margin) in the first half of... By: Andrew Cass * The hospitals, health systems cutting jobs in 2026 A number of hospitals and health systems are reducing their workforces amid ongoing financial strain. Executives have cited a mix... Kelly Gooch and Kristin Kuchno
Custom PCR solutions for diagnostic kit manufacturers. Drawing on its trusted 4titude portfolio of PCR products, Azenta Life Sciences has built a reputation for partnering with diagnostic kit manufacturers to develop consumables tailored to their specific workflows As molecular diagnostics continue to drive advances in healthcare, manufacturers face growing pressure to deliver high-quality, scalable diagnostic kits while meeting stringent requirements. Not all applications are soluble using off-the-shelf solutions. To support these evolving needs, Azenta Life Sciences offers customised molecular diagnostics solutions that combine proven PCR consumables with bespoke design and manufacturing expertise. Whether adapting existing products or creating entirely custom solutions, the company offers flexible options across PCR plates, sealing materials, sample tracking and automation-compatible consumables to help customers improve reproducibility, simplify manufacturing and accelerate product development. Baskar Anand, Global Product Manager at Azenta, said: "Our customisation capabilities extend from concept through to production." "Customers can specify plate formats, frame and well colours, coatings, surface treatments, seal materials, printing, chemical compatibility and barcode or 2D coding options, alongside contract manufacturing to create solutions that exactly fit your application." He added: "Our customers need more than a catalogue of consumables; they need solutions designed around their manufacturing processes. "By combining high-quality products with flexible customisation, we're helping diagnostic kit manufacturers build workflows that are efficient, reproducible and ready to scale." Azenta has worked with manufacturers to develop customised solutions for applications, including infectious disease diagnostics, supporting automated reagent dispensing, secure heat sealing, sample traceability and compatibility with downstream analytical platforms. All custom products supplied by Azenta are manufactured in ISO9001- and ISO13485-certified facilities, providing the quality systems, consistency and supply reliability required by diagnostic kit manufacturers worldwide. * Companies: * Azenta
Why Azenta (AZTA) stock is down today. What Happened? Shares of life sciences company Azenta AZTA fell 9.1% in the afternoon session after the company announced, in a regulatory filing, that President and CEO John Marotta resigned from his executive roles and board seat, with current director Dr. Martin Madaus appointed as interim President and CEO. Dr. Madaus, who joined the board in 2024 and serves as a Senior Operating Executive at the Carlyle Group, brings extensive executive experience from previous leadership roles at Millipore Corporation, Ortho-Clinical Diagnostics, and Roche Diagnostics North America. Azenta confirmed that executive search firm Heidrick & Struggles has been retained to identify a permanent successor. In addition to the management change, the company reaffirmed its fourth-quarter fiscal 2026 revenue guidance but noted that fourth-quarter adjusted EBITDA will be reduced by a one-time consulting expense of approximately $3 million. What Is The Market Telling Us Azenta's shares are extremely volatile and have had 30 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business. The biggest move we wrote about over the last year was 7 months ago when the stock dropped 24.6% on the news that it reported mixed fourth-quarter results that failed to impress investors. While the company's revenue of $148.6 million was flat year over year, it did narrowly beat Wall Street's estimates. Similarly, its adjusted earnings per share of $0.14 met expectations. However, the positive notes were overshadowed by a significant miss on profitability. Azenta's adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization), a key measure of operational profitability, was $12.7 million, falling 29% short of the consensus forecast. The company's cash generation also weakened, with its free cash flow margin declining to 9.9% from 14.9% in the same quarter last year. Overall, the stagnant sales growth and considerable weakness in underlying profitability signaled to investors that the company's financial health was not as strong as hoped, leading to a sharp sell-off. Azenta is up 1.5% since the beginning of the year, but at $33.89 per share, it is still trading 17.4% below its 52-week high of $41.01 from January 2026. Despite the year-to-date gain, investors who bought $1,000 worth of Azenta's shares 5 years ago would now be looking at only $414.94. ONE MORE THING: The $21 AI Application Stock Wall Street Forgot. While Wall Street obsesses over who's building AI, one company is already using it to print money. And nobody's paying attention. AI chip stocks trade at ridiculous valuations. This company processes a trillion consumer signals monthly using AI and trades at a third of the price. The gap won't last. The institutions will figure it out. You need to see this first. Read the FREE Report Before They Notice.
AZENTA announces leadership transition. Aug 24, 2026, 08:00 ET Current Director Dr. Martin Madaus Appointed Interim CEO Company Reaffirms Previously Announced Fourth Quarter Fiscal 2026 Total Revenue Guidance BURLINGTON, Mass., Aug. 24, 2026 /PRNewswire/ - Azenta, Inc. (Nasdaq: AZTA) ("Azenta" or "the Company") today announced that current member of the Board of Directors (the "Board") Dr. Martin Madaus has been appointed interim President and CEO, and that John Marotta has resigned as an executive officer and director of the Company. Dr. Madaus has served in multiple CEO roles in the diagnostics and life science tools industry and joined the Azenta Board in 2024 - making him the ideal individual to lead the Company during this transition. He is a Senior Operating Executive at the Carlyle Group Inc. (Nasdaq: CG) and has a proven track record of creating shareholder value in both public and private life science companies. Notably, he has served as Chairman, President and CEO of Millipore Corporation, Chairman and CEO of Ortho-Clinical Diagnostics, and President and CEO of Roche Diagnostics North America, a subsidiary of Roche Holding AG. The Board has retained leading search firm Heidrick & Struggles, and a search process for a permanent CEO is underway. Additionally, the Company is reaffirming its fourth quarter fiscal 2026 total revenue guidance previously issued on August 4, 2026. The Company now expects fourth quarter fiscal 2026 adjusted EBITDA to be impacted by a one-time approximately $3 million consulting expense that will be recorded in the fourth quarter. Excluding this one-time charge, the Company would be reaffirming adjusted EBITDA as well. Frank E. Casal, Chairman of the Azenta Board, said, "Azenta's focus remains on executing our long-range strategic plan to drive profitable, sustainable value creation. The Board regularly analyzes the performance of our core business units and will continue to evaluate which areas merit targeted reinvestments, while also maintaining a disciplined approach to capital deployment. As discussed on our third quarter earnings call earlier this month, we have seen notable progress in terms of revenue and profitability, and the Board is confident that Martin is the ideal choice to help build on this positive momentum and guide Azenta during this transition period. His track record of successful leadership in our sector speaks for itself, and we believe his deep familiarity with our businesses from his time on the Board will help allow for a seamless transition for our customers, partners, and employees." Dr. Madaus said, "I am pleased to be taking on this role and look forward to leading Azenta as we continue to focus on disciplined execution and advancing key initiatives in support of our strategic plan. I have long admired Azenta as a leader in the space and believe that, with the support of the Company's incredibly talented team, we can accelerate our efforts to meet our commitments and deliver value for shareholders." Mr. Casal continued, "On behalf of the Board, I would like to thank John for his contributions to Azenta." Dr. Martin Madaus Full Biography Dr. Martin Madaus has more than 30 years of leadership experience in diagnostics and life science tools, both as an executive and a board member. He is a Senior Operating Executive at the Carlyle Group Inc. (Nasdaq: CG), a global investment firm with $485 billion in assets under management. In addition to the Board of Azenta, he also currently serves as Chair of the Board of Repligen Corporation and as a director at Haemonetics Corporation (NYSE: HAE). He previously served as Chairman and CEO at Ortho-Clinical Diagnostics (now QuidelOrtho Corporation), Chairman, President and CEO of Millipore Corporation, and President and CEO of Roche Diagnostics North America, a subsidiary of Roche Holding AG (SWX: ROG). He earned a Doctor of Veterinary Medicine Degree from the University of Munich, Germany, and a Ph.D. in Veterinary Medicine from the Veterinary University of Hannover, Germany. "Safe Harbor Statement" under Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended Some statements in this release are forward-looking statements made under Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are neither promises nor guarantees but involve risks and uncertainties, both known and unknown, that could cause Azenta's actual financial and business results to differ materially from those expressed or implied by such statements. They are based on the facts and assumptions known to management at the time they are made. Forward looking statements include, but are not limited to, statements regarding the Company's guidance, the Company's long-range plan, the Company's analyses of its core business units and its investments and capital deployment and the Company's expectations with respect to Dr. Madaus' role as Interim President and CEO and his impact on the Company's business, customers, partners, employees and shareholders. Factors that could cause actual results to differ materially from those expressed or implied by forward looking statements include, but are not limited to: the Company's ability to ensure a smooth CEO transition; the Company's ability to execute on and realize the expected benefits from its transformation and operational improvement initiatives; changes in customer demand, purchasing behavior or funding conditions in the markets the Company serves; macroeconomic, geopolitical or regulatory developments; the impact of foreign currency fluctuations; the Company's ability to effectively manage costs, improve productivity and achieve anticipated margin improvements; supply chain disruptions; competitive dynamics; the ability of customers to meet payment obligations; risks relating to the collectability and timely repayment of the $35 million secured vendor loan extended to the buyer in connection with the B Medical Systems divestiture, including the buyer's ability to obtain permanent financing, the sufficiency of the collateral securing the loan, and the potential for an associated charge or impairment; and other risks and uncertainties described in the Company's filings with the Securities and Exchange Commission, including but not limited to its Annual Report on Form 10 K, Quarterly Reports on Form 10 Q and Current Reports on Form 8 K. Because forward looking statements relate to future events and are based on current expectations, they are inherently subject to significant uncertainties, particularly with respect to projections and assumptions extending over multiple years. As a result, actual outcomes may differ materially from those projected. Azenta expressly disclaims any obligation or undertaking to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. About Azenta Life Sciences Azenta, Inc. (Nasdaq: AZTA) is a leading provider of life sciences solutions worldwide, enabling life science organizations around the world to bring impactful breakthroughs and therapies to market faster. Azenta provides a full suite of reliable cold-chain sample management solutions and multiomics services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. Our global team delivers and supports these products and services through our industry-leading brands, including GENEWIZ, FluidX, Ziath, 4titude, Limfinity, Freezer Pro, and Barkey. Azenta is headquartered in Burlington, Massachusetts, with operations in North America, Europe, and Asia. For more information, please visit www.azenta.com. AZENTA INVESTOR CONTACTS: Yvonne Perron Vice President, Financial Planning & Analysis and Investor Relations [email protected] Maria Isabel Cuartas Manager Investor Relations [email protected] AZENTA MEDIA CONTACT: Joe Germani / Dan Zacchei Longacre Square Partners [email protected] SOURCE Azenta
Azenta Life Sciences' custom PCR solutions for diagnostic kit manufacturers. Published: 18 August 2026 Expanding on its 4titude portfolio of PCR products, Azenta Life Sciences has built a reputation for partnering with diagnostic kit manufacturers to develop consumables tailored to their specific workflows As molecular diagnostics drive advances in healthcare, manufacturers are under mounting pressure to provide high-quality, scalable diagnostic kits while meeting stringent requirements. Not all applications are soluble using off-the-shelf solutions. Azenta Life Sciences offers customised molecular diagnostic solutions to support these evolving needs. The solutions combine proven PCR consumables with bespoke design and manufacturing expertise. Whether adapting existing products or creating custom solutions, the company provides flexible options across PCR plates, sealing materials, sample tracking, and automation-compatible consumables to help customers enhance reproducibility, simplify manufacturing, and accelerate product development. Baskar Anand, global product manager, Azenta, said, "Its customisation capabilities extend from concept through to production. Customers can specify plate formats, frame and well colours, coatings, surface treatments, seal materials, printing, chemical compatibility, and barcode or 2D coding options, alongside contract manufacturing to create solutions that exactly fit your application. "Our customers need more than a catalogue of consumables - they need solutions designed around their manufacturing processes. By combining high-quality products with flexible customisation, we're helping diagnostic kit manufacturers build workflows that are efficient, reproducible, and ready to scale." Azenta works with manufacturers to develop customised solutions for applications such as infectious disease diagnostics, supporting automated reagent dispensing, secure heat sealing, sample traceability, and compatibility with downstream analytical platforms. Azenta manufactures custom products in ISO 9001- and ISO 13485-certified facilities, providing the quality systems, consistency, and supply reliability that a diagnostic kit manufacturer requires.